**Request Information** 



# A Synthetic Peptide for Use in Diagnosis and Treatment of Myasthenia Gravis

Tech ID: 27289 / UC Case 2017-074-0

# ABSTRACT

Researchers at the University of California, Davis have developed a peptide that could be used in the diagnosis and treatment of Myasthenia Gravis.

# **FULL DESCRIPTION**

Current treatment options for Myasthenia Gravis (MG) include immune suppression, plasmapheresis and the use of acetylcholine-esterase inhibitors. Although effective, these treatments either remedy symptoms over a short term cycle or carry the risks associated with immune suppression.

Researchers at the University of California, Davis have developed a peptide that could be used in the diagnosis and early treatment of MG. This peptide has very high affinity for the pathogenic autoantibodies that target the main immunogenic region of the nicotinic acetylcholine receptor. The peptide can be used to target and eliminate the B-cells that retain the blueprint for the pathogenic autoantibodies. This approach aims to cure the underlying cause of MG. This peptide could be used to screen for pathogenic autoantibodies, which could enable earlier detection of MG or earlier evaluation of MG therapeutic success.

# **APPLICATIONS**

- Allergies
- Autoimmune disorders
- Competitive inhibitors
- Immune system editing
- Early detection and treatment of Myasthenia Gravis

#### **FEATURES/BENEFITS**

- Auto-antibody specific targeting
- Avoids general immune suppression or invasive surgery

# PATENT STATUS

Country	Туре	Number	Dated	Case
United States Of America	Issued Patent	11,422,132	08/23/2022	2017-074

## CONTACT

Byron N. Roberts bnroberts@ucdavis.edu tel: 530-754-8689.



## INVENTORS

► Fairclough, Robert

Η.

▶ Trinh, Vu

## OTHER INFORMATION

**KEYWORDS** Myasthenia Gravis, autoimmune disorder, competitive inhibitor, autoantibody-specific targeting, immune system editing, allergies

#### **CATEGORIZED AS**

#### Materials &

#### Chemicals

- Biological
- Medical
  - Diagnostics
  - Disease:
  - Autoimmune and
  - Inflammation
  - ► Therapeutics
- Research Tools

m editing

**RELATED CASES** 2017-074-0

University of California, Davis	Tel:	© 2016 - 2022, The Reger	nts of the University of
Technology Transfer Office	530.754.8649		California
1 Shields Avenue, Mrak Hall 4th Floor,	techtransfer@ucdavis.edu		Terms of use
Davis,CA 95616	https://research.ucdavis.edu/technology-		Privacy Notice
	<u>transfer/</u>		
	Fax:		
	530.754.7620		